Refine Search

Search Results -

Terms	Documents	
L1 and (factor adj1 VIII)	40	

US Pre-Grant Publication Full-Text Database US Patents Full-Text Database US OCR Full-Text Database **EPO Abstracts Database**


JPO Abstracts Database

Derwent World Patents Index


IBM Technical Disclosure Bulletins

Search:

Database:











Search History

DATE: Tuesday, May 15, 2007 **Purge Queries** Printable Copy Create Case

Set Name Query **Hit Count Set Name** side by side result set DB=PGPB, USPT, USOC, EPAB, JPAB, DWPI, TDBD; PLUR=YES; OP=OR L2 L1 and (factor adj1 VIII) L2 40 L1 (encod\$ adj3 factor) same liposome 119 L1

END OF SEARCH HISTORY

First Hit Fwd Refs

Previous Doc Next Doc Go to Doc#

Generate Collection Print

L2: Entry 38 of 40

File: USPT

Dec 22, 1998

DOCUMENT-IDENTIFIER: US 5851818 A

TITLE: Condensed plasmid-liposome complex for transfection

Brief Summary Text (26):

The plasmid-liposome complex prepared according to the method of the invention, in one embodiment, is for use in transfecting a host cell with a gene contained in a DNA plasmid, where the DNA plasmid contains a gene selected from the group consisting of genes encoding for Factor VIII, interleukin-2 or p53.

Detailed Description Text (19):

In the first are those genes which are intended to overcome a gene deficiency or defect in the subject, i.e., where the subject fails to produce active, endogenous protein at all or within normal levels, and the gene introduced in the plasmid is intended to make up this deficiency. Examples of this class of genes include genes encoding adenosine deaminase (ADA), for gene expression in stem cells or lymphocytes; genes encoding purine nucleoside phosphorylase deficiency, deficiency in prostaglandin G/H synthase, therapy of Lesch-Nyhan syndrome caused by a deficiency in hypoxanthine-guanine phosphoribosyltransferase, genes encoding a variety of circulating proteins, such as .alpha..sub.1 -antitrypsin, clotting factors (e.g., Factor VIII, Factor IX) and globins (e.g., .beta.-globin, hemoglobin), for the treatment of hemophilia, sickle-cell anemia and other blood-related diseases, and genes encoding hormones and other peptide regulators.

Previous Doc Next Doc Go to Doc#

First Hit Fwd Refs

Previous Doc Next Doc Go to Doc#

Cenerate Collection Print

L2: Entry 30 of 40

File: USPT

Feb 11, 2003

US-PAT-NO: 6517830

DOCUMENT-IDENTIFIER: US 6517830 B1

** See image for Certificate of Correction **

TITLE: Compositions and methods for the expression of $\underline{\text{factor VIII}}$ polypeptides and uses therefor

DATE-ISSUED: February 11, 2003

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Lollar; John S. Decatur GA
Do; Hung V. Atlanta GA
Healey; John F. Snellville GA
Waller; Edmund K. Atlanta GA

ASSIGNEE-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY TYPE CODE

Emory University Atlanta GA 02

APPL-NO: 09/633020 [PALM]
DATE FILED: August 4, 2000

PARENT-CASE:

CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Application Ser. No. 60/147,407, filed Aug. 5, 1999, the contents of which are herein incorporated by reference.

INT-CL-ISSUED: [07] A01N 63/00, A61K 48/00

INT-CL-CURRENT:

TYPE IPC DATE
CIPN A61 K 48/00 20060101
CIPS C07 K 14/435 20060101
CIPS C07 K 14/755 20060101
CIPS C12 P 21/02 20060101

US-CL-ISSUED: 424/93.21; 514/44, 435/320.1 US-CL-CURRENT: 424/93.21; 435/320.1, 514/44

FIELD-OF-CLASSIFICATION-SEARCH: 514/44, 435/720.1, 424/93.21 See application file for complete search history.

PRIOR-ART-DISCLOSED:

U.S. PATENT DOCUMENTS

Search Selected Search ALL Clear

	PAT-NO	ISSUE-DATE	PATENTEE-NAME	US-CL
	4868112	September 1989	Toole, Jr.	435/68
	5681746	October 1997	Bodner	
Ę	5744446	April 1998	Lollar	
	6087129	July 2000	Newgard	

OTHER PUBLICATIONS

Riddell et al., T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients, 1996, Nature Medicine, vol. 2, pp. 216-223.* Cid-Arregui et al., Viral Vectors: Basic science and gene therapy, 2000, Biotechniques Books, pp. 223.*

Chiu et al., Optimizing energy potentials for success in protein tertiary structure prediction, 1998, Folding & Design, vol. 3, pp. 223-228.*

Hegenbarth et al., Liver sinusoidal endothelial cells are not permissive for adenovirus 2000, Human Gene Therapy, vol. 11, pp. 481-486.*

Walter et al., Gene therapy for the hemophilas 1997, Advances in Veterinary Medicine, vol. 40, pp. 119-134.*

Freiburghaus et al., Tolerance induction using the Malmo treatment model 1982-1995, 1999, Haemophilia, vol. 5, pp. 32-39.*

Connelly et al. (1996) "High-Level Tissue-Specific Expression of Functional Human Factor VIII in Mice" Human Gene Therapy 7:183-195.

Connelly et al. (1998) "Sustained Phenotypic Correction of Murine Hemophilia A by In Vivo Gene Therapy" Blood 91(9):3273-3281.

Do et al. (1999) "Expression of <u>Factor VIII</u> by Murine Liver Sinusoidal Endothelial Cells" J. Biol. Chem. 274(28):19587-19592.

Hellman et al. (1989) "Secretion of Coagulant <u>Factor VIII</u> Activity and Antigen by In Vitro Cultivated Rat Liver Sinusoidal Endothelial Cells" British J. Haematology 73:348-355.

Herzog et al. (1998) "Problems and Prospects in Gene Therapy for Hemophilia" Current Opinion in Hematology 5(5):321-326.

Ill et al. (1997) "Optimization of the Human <u>Factor VIII</u> Complementary DNA Expression Plasmid for Gene Therapy of Hemophilia A" Blood Coagulation and Fibrinolysis 8(Suppl 2):S23-S30.

Kadhom et al. (1988) "Factor VIII Procoagulant Antigen in Human Tissues" Thrombosis and Haemostasis 59(2):289-294.

Kwast et al. (1986) "Localization of $\underline{Factor\ VIII}$ -Procoagulant Antigen: An Immunohistological Survey of the Human Body Using Monoclonal Antibodies" Blood 67 (1):222-227.

Lenting et al. (1998) "The Life Cycle of Coagulation Factor VIII in View of Its Structure and Function" Blood 92(11):3983-3996.

Shima et al. (1988) "Factor VIII Polypeptide Specificity of Monoclonal Anti-factor VIII Antibodies" British J. Haematology 70:63-69.

Stel et al. (1983) "Detection of <u>Factor VIII</u>/Coagulant Antigen in Human Liver Tissue" Nature 303:530-532.

Van Der Eb et al. (1996) "Liver-Directed Gene Therapy for <u>Factor-VIII</u> Deficiency" J. Clinical Biochemistry and Nutrition21(1):78-80.

Wion et al. (1985) "Distribution of $\underline{Factor\ VIII}$ mRNA and Antigen in Human Liver and Other Tissues" Nature 317:726-729.

Zelechowska et al. (1985) "Ultrastructural Localization of Factory VIII Procoagulant Antigen in Human Liver Hepatocytes" Nature 317:729-730.

ART-UNIT: 1635

PRIMARY-EXAMINER: Nguyen; Dave T.

ASSISTANT-EXAMINER: Whiteman; Brian

ATTY-AGENT-FIRM: Alston & Bird LLP

ABSTRACT:

Compositions and methods are provided for the in vivo gene delivery of nucleic acid sequences encoding the $\underline{factor\ VIII}$ protein to the liver endothelial sinusoidal cells (LSECs). Compositions and methods are also provided for the ex vivo gene transfer of nucleic acid sequences encoding the $\underline{factor\ VIII}$ protein to cultured LSECs and the implantation of the transformed LSECs in vivo. These methods and compositions increase the level of $\underline{factor\ VIII}$ in the blood stream and find use in the gene therapy treatment of hemophilia A.

12 Claims, 4 Drawing figures

Previous Doc Next Doc Go to Doc#

First Hit Fwd Refs

Previous Doc Next Doc Go to Doc#

Generate Collection Print

L2: Entry 35 of 40

File: USPT

Oct 17, 2000

DOCUMENT-IDENTIFIER: US 6133026 A

TITLE: Condensed plasmid-liposome complex for transfection

Brief Summary Text (22): .

In one embodiment, the condensed plasmid molecules are DNA plasmid molecules containing a gene selected from the group consisting of genes encoding for cystic fibrosis transmembrane conductance regulator, Factor VIII, interleukin-2 or p53.

Brief Summary Text (31):

The plasmid-liposome complexes prepared according to the method of the invention, in one embodiment, are for use in transfecting a host cell with a gene contained in a DNA plasmid, where the DNA plasmid contains a gene selected from the group consisting of genes encoding for Factor VIII, interleukin-2 or p53.

Detailed Description Text (24):

In the first are those genes which are intended to overcome a gene deficiency or defect in the subject, i.e., where the subject fails to produce active, endogenous protein at all or within normal levels, and the gene introduced in the plasmid is intended to make up this deficiency. Examples of this class of genes include genes encoding adenosine deaminase (ADA), for gene expression in stem cells or lymphocytes; genes encoding purine nucleoside phosphorylase deficiency, deficiency in prostaglandin G/H synthase, therapy of Lesch-Nyhan syndrome caused by a deficiency in hypoxanthine-guanine phosphoribosyltransferase, genes encoding a variety of circulating proteins, such as .alpha..sub.l -antitrypsin, clotting factors (e.g., Factor VIII, Factor IX) and globins (e.g., .beta.-globin, hemoglobin), for the treatment of hemophilia, sickle-cell anemia and other blood-related diseases, and genes encoding hormones and other peptide regulators.

CLAIMS:

2. The composition of claim 1, wherein the condensed plasmid molecules are DNA plasmid molecules containing a gene selected from the group consisting of genes encoding for cystic fibrosis transmembrane conductance regulator, <u>Factor VIII</u>, interleukin-2 and p53.

Previous Doc Next Doc Go to Doc#